[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658475":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":16,"studyPopulation":16,"armGroups":37,"interventions":47,"overallOfficials":16,"centralContacts":55,"locations":16,"responsibleParty":62,"collaborators":16,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":16,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":16,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":16,"overallStatus":85,"whyStopped":16,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":16},{"fullName":5,"class":6},"Sanofi","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Rilzabrutinib: AUC","area under the plasma concentration versus time curve","Until Day 2",[14,17,19,21,23,25,27],{"measure":15,"description":16,"timeFrame":12},"Rilzabrutinib: Cmax",null,{"measure":18,"description":16,"timeFrame":12},"Rilzabrutinib: unbound Cmax",{"measure":20,"description":16,"timeFrame":12},"Rilzabrutinib: AUClast",{"measure":22,"description":16,"timeFrame":12},"Rilzabrutinib: unbound AUC",{"measure":24,"description":16,"timeFrame":12},"Rilzabrutinib: CL\u002FF",{"measure":26,"description":16,"timeFrame":12},"Rilzabrutinib: t1\u002F2z",{"measure":28,"description":29,"timeFrame":30},"Adverse events (AEs)","incl. Clinical laboratory evaluations, Vital signs, Electrocardiogram (ECG)","Until Day 3",{"allocation":32,"interventionModel":33,"interventionModelDescription":16,"primaryPurpose":34,"observationalModel":16,"timePerspective":16,"maskingInfo":35},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":16,"whoMasked":16},"NONE",[38,44],{"label":39,"type":40,"description":41,"interventionNames":42},"Participants with severe renal impairment","EXPERIMENTAL","Treated with single dose of rilzabrutinib",[43],"Drug: rilzabrutinib",{"label":45,"type":40,"description":41,"interventionNames":46},"Participants with normal renal function",[43],[48],{"type":49,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"DRUG","rilzabrutinib","Pharmaceutical form: Tablet Route of administration: Oral",[45,39],[54],"SAR444671",[56],{"name":57,"role":58,"phone":59,"phoneExt":60,"email":61},"Trial Transparency email recommended (Toll free for US & Canada)","CONTACT","800-633-1610","option 6","Contact-US@sanofi.com",{"type":63,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100658475","phase-1-study-to-assess-the-plasma-concentration-of-rilzabrutinib-given-as-a-tablet-to-adult-participants-with-severe-renal-impairment-compared-to-matched-participants-with-normal-renal-function-100658475",false,"NCT07853131","Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function","An Open-label, Multi-center, Phase 1 Pharmacokinetic and Tolerability Study of Rilzabrutinib Given as a Single Oral Dose in Participants With Severe Renal Impairment and in Matched Participants With Normal Renal Function","Inclusion Criteria:\n\n* If participants with severe renal impairment: Stable severe chronic kidney disease (no dialysis) assessed by medical history, physical examination, laboratory values.\n* If participants with normal renal function: Certified as healthy by a comprehensive clinical assessment.\n* Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, and BMI between 18.0 and 40.0 kg\u002Fm2, inclusive, at screening.\n* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* Regular intake of nicotine more than 10 mg per day and unable to stop smoking during the study (occasional smoker can be enrolled).\n* History or presence of drug or alcohol abuse.\n* If participants with severe renal impairment:\n\n  * Uncontrolled cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not clinically significant.\n  * Participants with a history of serious infection requiring intravenous therapy within 4 weeks of study enrollment.\n  * Any significant change in chronic treatment medication within 14 days before inclusion.\n* If participants with normal renal function\n\n  * Any history or presence of clinically relevant hepatic or renal disease.\n  * For participants 50 years of age and younger: Any history or presence of cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not clinically significant.\n  * For participants above 50 years of age: Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness, unless the Investigator considers an abnormality to be not clinically significant.\n  * Frequent headaches and\u002For migraine, recurrent nausea and\u002For vomiting. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",true,"ALL","18 Years","75 Years",{"count":76,"type":77},16,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The purpose of this Phase 1, open-label, 2-arm study is to assess the effect of severe RI on PK, safety, and tolerability of rilzabrutinib compared with normal renal function, in male and female participants aged from 18 to 75 years.\n\nThe total duration of the study per participant will be approximately 30 days, including:\n\n* A screening period of up to 27 days.\n* A 3-day, open-label treatment period, with a single dose on Day 1.\n* A 1-day follow-up period (Day 3) with an allowable 2-day window (ie, Day 3 to Day 5).",[83,84],"Renal Impairment","Healthy Volunteers","NOT_YET_RECRUITING","2026-09-23",{"date":88,"type":89},"2026-10-01","ACTUAL",{"date":91,"type":77},"2026-10-09",{"date":93,"type":77},"2027-04-21",{"name":5,"class":6}]